Search results for "Nebulizer"

showing 10 items of 30 documents

Effects of inhaled corticosteroids, leukotriene receptor antagonists, or both, plus long-acting beta2-agonists on asthma pathophysiology: a review of…

2004

Chronic inflammation and smooth muscle dysfunction are consistent features of asthma, and are responsible for disease progression and airway remodelling. The development of chronic airway inflammation depends upon the recruitment and activation of inflammatory cells and the subsequent release of inflammatory mediators, including cytokines. Cellular and histological evaluation of drugs with anti-inflammatory activity, such as inhaled corticosteroids (ICSs), is achieved by analysing samples of lung tissue or biological fluids, obtained by techniques such as bronchial biopsy, bronchoalveolar lavage and sputum induction. These provide valuable information on the inflammatory processes occurring…

Pathophysiology of asthmamedicine.drug_classInflammationAdrenal Cortex HormonesBronchodilatorAdministration InhalationmedicineHumansPharmacology (medical)Adrenergic beta-2 Receptor AgonistsAsthmaLungmedicine.diagnostic_testLeukotriene receptorbusiness.industryNebulizers and Vaporizersmedicine.diseaseAsthmarespiratory tract diseasesmedicine.anatomical_structureBronchoalveolar lavageDelayed-Action PreparationsImmunologyLeukotriene AntagonistsBronchoconstrictionDrug Therapy CombinationReceptors Adrenergic beta-2medicine.symptombusinessDrugs
researchProduct

Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants

2014

Acute bronchiolitis is the leading cause of lower respiratory t ract infection and hospitalization in children less than 1y ear of age worldwide. It is usually a mild disease, but some children may develop severe symptoms, requiring hospital admission and ventilatory support in the ICU. Infants with pre-existing risk factors (prematurity, bronchopulmonary dysplasia, congenital heart diseases and immunodeficiency) may be predisposed to a severe form of the disease. Clinical diagnosis of bronchiolitis is manly based on medical history and physical examination (rhinorrhea, cough, crackles, wheezing and signs of respiratory distress). Etiological diagnosis, with antigen or genome detection to i…

PediatricsBronchiolitis; Bronchopulmonary dysplasia; Congenital heart diseases; Immunodeficiency; Oxygen therapy; Prematurity; Prevention; Prophylaxis; Respiratory syncytial virus;ReviewRespiratory syncytial virusSeverity of Illness IndexCongenital heart diseasesSettore MED/38 - Pediatria Generale E SpecialisticaAdrenergic beta-2 Receptor AntagonistsVitamin DChildrenRespiratory distressVitaminsEnvironmental exposurePatient DischargeAnti-Bacterial AgentsBronchodilator AgentsHospitalizationSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICABronchiolitisbronchiolitisPrematuritymedicine.drugPalivizumabRespiratory Therapymedicine.medical_specialtyEpinephrineDecision MakingAntibodies Monoclonal HumanizedAntiviral AgentsIntensive Care Units NeonatalBronchiolitis Respiratory syncytial virus Prematurity Bronchopulmonary dysplasia Congenital heart diseases Immunodeficiency Oxygen therapy Prevention ProphylaxismedicineHumansImmunodeficiencyAcute bronchiolitisMedical historyConsensus DocumentIntensive care medicineGlucocorticoidsPalivizumabAsthmaSaline Solution HypertonicPrimary Health CareProphylaxisbusiness.industryNebulizers and VaporizersPreventionInfant NewbornOxygen Inhalation TherapyHumidityEnvironmental ExposureAcute bronchiolitis Consensus Documentmedicine.diseaseBronchopulmonary dysplasiaOxygen therapyHypertonic salineBronchopulmonary dysplasiaBronchiolitisbusinessItalian Journal of Pediatrics
researchProduct

Does the frequency of switching inhalers represent a predictive factor of exacerbation in asthma?

2020

Objective: Management of asthma includes monitoring of inhaler technique and level of adherence to treatment. Both factors could be influenced by high frequency of switching inhaler devices. We explored whether switching inhalers is an independent predictive factor of exacerbations. Methods: Data were collected from 2015 to 2017 from the outpatient clinic of asthma at the University of Palermo, Italy. This observational study consisted of two phases: Phase 1 included subjects of at least three visits in the previous year who reported the frequency of inhalers switched; Phase 2 included subjects of at least two visits during the second year, and the rate of switches and exacerbations was rec…

Pulmonary and Respiratory MedicineAdultmedicine.medical_specialtyExacerbationSettore MED/10 - Malattie Dell'Apparato Respiratorioexacerbation: inhaler03 medical and health sciencesYoung Adult0302 clinical medicineAdrenal Cortex HormonesAdministration InhalationmedicineImmunology and AllergyHumans030212 general & internal medicineAnti-Asthmatic AgentsIntensive care medicinedeviceAsthmaAgedAged 80 and overbusiness.industryInhalerNebulizers and VaporizersMiddle Agedmedicine.diseaseAsthmaswitchPredictive factorHospitalization030228 respiratory systemPediatrics Perinatology and Child Healthbusiness
researchProduct

The inhalation manager: a new computer-based device to assess inhalation technique and drug delivery to the patient.

2003

The rational choice of an inhalation device is a cornerstone in the effective management of asthma and COPD. In this publication, we describe the development of a new system, the Inhalation Manager, which, for the first time, offers the possibility to assess the entire inhalation maneuver of patients using original devices under everyday conditions. So far the Inhalation Manager allows the measurement of inspiratory maneuvers of patients through placebo inhalation devices of the most common breath-actuated CFC-free inhalers in the market for the three main glucocorticosteroids Budesonide [Turbohaler (TH), dry powder inhaler (DPI)], Beclomethasone dipropionate [Autohaler (AH), breath-actuate…

Pulmonary and Respiratory MedicineBudesonideAdultMaleInhalationAdolescentbusiness.industryInhalerNebulizers and VaporizersBeclometasone dipropionateMiddle AgedMetered-dose inhalerDry-powder inhalerFluticasone propionateDrug Delivery SystemsAnesthesiamedicineHumansPharmacology (medical)FemaleParticle SizebusinessFluticasonemedicine.drugJournal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine
researchProduct

Physicochemical compatibility of mixtures of dornase alfa and tobramycin containing nebulizer solutions

2008

Patients suffering from cystic fibrosis (CF) often need to inhale multiple doses of different nebulizable drugs per day. Patients attempt to shorten the time consuming administration procedure by mixing drug solutions/suspensions for simultaneous inhalation. The objective of this experimental study was to determine whether mixtures of the nebulizer solution dornase alfa (Pulmozyme) with tobramycin nebulizer solutions (TOBI and GERNEBCIN 80 mg) are physico-chemically compatible. Drug combinations were prepared by mixing the content of one respule Pulmozyme with either one respule TOBI or one ampoule GERNEBCIN 80 mg. Test solutions were stored at room temperature and exposed to light. Dornase…

Pulmonary and Respiratory MedicineChemical PhenomenaCystic FibrosisExcipientAmpouleDrug Incompatibilitychemistry.chemical_compoundAdministration InhalationTobramycinDeoxyribonuclease IHumansMedicinePotencyChromatographyInhalationbusiness.industryNebulizers and VaporizersDornase alfaSodium metabisulfiteAnti-Bacterial AgentsDrug CombinationsPharmaceutical SolutionsNebulizerchemistryAnesthesiaPediatrics Perinatology and Child HealthTobramycinbusinessmedicine.drugPediatric Pulmonology
researchProduct

Physicochemical compatibility and stability of nebulizable drug admixtures containing Dornase alfa and tobramycin.

2012

The objective of this in-vitro study was to determine whether admixtures of the inhalation solutions Pulmozyme(®) (Dornase alfa) and either Bramitob(®) or Tobi(®) (both containing Tobramycin) are physicochemically compatible and to analyze the aerodynamic parameters of these admixtures. After mixing, test solutions were stored at room temperature and under ambient light conditions over a period of 24 h. Tobramycin concentrations were determined by using a fluorescence immunoassay. Stability of dornase alfa was determined by size-exclusion high performance liquid chromatography, ultraviolet spectroscopy, sodium dodecyl sulfate polyacrylamide gel electrophoresis and tentacle strong cation-exc…

Pulmonary and Respiratory MedicineTime FactorsDrug StorageHigh-performance liquid chromatographyDrug Incompatibilitychemistry.chemical_compoundDrug StabilityAdministration InhalationmedicineTobramycinGeometric standard deviationDeoxyribonuclease IPharmacology (medical)Sodium dodecyl sulfateParticle SizeAerosolsChromatographyInhalationNebulizers and VaporizersBiochemistry (medical)Osmolar ConcentrationDornase alfaHydrogen-Ion ConcentrationRecombinant ProteinsAnti-Bacterial AgentsDrug CombinationsPharmaceutical SolutionschemistryCompatibility (mechanics)TobramycinFeasibility StudiesParticle fractionmedicine.drugPulmonary pharmacologytherapeutics
researchProduct

A simple method of bronchoprovocation using a valved holding chamber.

2004

This study was undertaken to ascertain whether the use of a valved holding chamber (VHC) during bronchial provocation testing might increase lung deposition and repeatability of the test relative to the tidal breathing method. The 2-min tidal breathing results were compared to five inhalations from a VHC device in patients using the Pari-provoII nebulizer (MMD = 2.1mkm). Lung and mouth deposition, losses though the exhaled air and losses before aerosol delivery to the patient's mouth were measured in patients using a radiolabeled 99Tc-DTPA solution and gamma camera. The study revealed that lung deposition was 67% with the VHC method, and losses with exhaled air were 29% of the inhaled amoun…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyBronchial Provocation TestsTidal VolumeMedicineHumansPharmacology (medical)In patientRadionuclide ImagingLungAerosolsLungbusiness.industryNebulizers and VaporizersRepeatabilityrespiratory systemHOLDING CHAMBERrespiratory tract diseasesSurgeryAerosolNebulizermedicine.anatomical_structureBronchial provocationTechnetium Tc 99m PentetateRadiopharmaceuticalsbusinessNuclear medicineDeposition (chemistry)Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine
researchProduct

Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases?

2015

Inhalation is the preferred route of drug administration in chronic respiratory diseases because it optimises delivery of the active compounds to the targeted site and minimises side effects from systemic distribution. The choice of a device should be made after careful evaluation of the patient's clinical condition (degree of airway obstruction, comorbidities), as well as their ability to coordinate the inhalation manoeuvre and to generate sufficient inspiratory flow. These patient factors must be aligned with the specific advantages and limitations of each inhaler when making this important choice. Finally, adherence to treatment is not the responsibility of the patient alone, but should …

Pulmonary and Respiratory Medicinemedicine.medical_specialtyChronic ObstructiveSocio-culturaleSettore MED/10 - Malattie Dell'Apparato RespiratorioAffect (psychology)Anti-asthmatic AgentMedication AdherencePulmonary DiseasePulmonary Disease Chronic ObstructiveSuspensionsAdministration InhalationmedicineCOPDHumansPharmacology (medical)Anti-Asthmatic AgentsMetered Dose InhalersRespiratory systemParticle SizeIntensive care medicineAsthmaAdherence; Asthma; COPD; Inhaler; Administration Inhalation; Anti-Asthmatic Agents; Dry Powder Inhalers; Humans; Medication Adherence; Metered Dose Inhalers; Particle Size; Pulmonary Disease Chronic Obstructive; Solutions; Suspensions; Nebulizers and Vaporizers; Pulmonary and Respiratory Medicine; Pharmacology (medical); Biochemistry (medical); Medicine (all)COPDInhalationbusiness.industryMedicine (all)InhalerNebulizers and VaporizersBiochemistry (medical)Adherence; Asthma; COPD; Inhaler; Administration Inhalation; Anti-Asthmatic Agents; Dry Powder Inhalers; Humans; Medication Adherence; Metered Dose Inhalers; Particle Size; Pulmonary Disease Chronic Obstructive; Solutions; Suspensions; Nebulizers and Vaporizers; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)InhalerDry Powder InhalersAirway obstructionmedicine.diseaseAsthmaSolutionsInhalationAdherenceAdministrationAdherence; Asthma; COPD; InhalerbusinessPulmonary pharmacologytherapeutics
researchProduct

Fluticasone propionate/formoterol: a fixed-combination therapy with flexible dosage.

2014

International guidelines describe asthma control as the main outcome of asthma management. Prevention of symptoms, improved quality of life, and reduction of exacerbations are the main components, consequently decreasing health care costs. However, many of these objectives remain unmet in real life: several surveys show that a large proportion of asthmatic patients are not well controlled despite the efficacy of current available treatment. Several randomized controlled clinical trials indicate that combining inhaled corticosteroids and long-acting β2-agonists, by means of a single inhaler, greatly improves the management of the disease. The results of 9 multicenter phase III clinical studi…

medicine.medical_specialtyCombination therapyAsthma exacerbationSettore MED/10 - Malattie dell'Apparato RespiratorioSettore MED/10 - Malattie Dell'Apparato RespiratorioFluticasone propionateAsthma control; Asthma exacerbations; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhalerAsthma controlFluticasone propionate/formoterolForced Expiratory VolumeFormoterol FumarateInternal MedicineMedicineHumansAnti-Asthmatic AgentsAsthma exacerbationsParticle SizeIntensive care medicineAsthmaFluticasonebusiness.industryInhalerNebulizers and VaporizersFixed-combination therapyAsthma control; Asthma exacerbations; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhaler; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Drug Combinations; Ethanolamines; Fluticasone; Forced Expiratory Volume; Formoterol Fumarate; Humans; Nebulizers and Vaporizers; Particle Size; Quality of Life; Treatment Outcomemedicine.diseaseSingle-aerosol inhalerAsthmaBronchodilator AgentsAndrostadienesDrug CombinationsTreatment OutcomeTolerabilityAsthma control Asthma exacerbations Fixed-combination therapy Fluticasone propionate/formoterol Single-aerosol inhalerEthanolaminesAnesthesiaAsthma exacerbations; Asthma control; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhalerQuality of LifeFluticasoneFormoterol FumarateFormoterolbusinessmedicine.drugEuropean journal of internal medicine
researchProduct

Aerosolization Performance of Jet Nebulizers and Biopharmaceutical Aspects

2019

In this work, 13 jet nebulizers, some of which in different configurations, were investigated in order to identify the biopharmaceutical constraints related to the quality attributes of the medicinal products, which affect their safety, efficiency, compliance, and effectiveness. The aerosolization parameters, including the aerosol output, aerosol output rate, mass median aerodynamic diameter, and fine particle fraction, were determined according to the European Standard EN 13544-1, using sodium fluoride as a reference formulation. A comparison between the aerosol output nebulization time and the fine particle fraction displayed a correlation between the aerosol quality and the nebulization …

respirable dose delivery ratePharmaceutical SciencePatient characteristicslcsh:RS1-441030226 pharmacology & pharmacycomplex mixturesArticleNOlcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicineAerosol output Aerosol output rate Fine particle fraction Mass median aerodynamic diameter Nebulizers Respirable delivered dose Respirable dose delivery rateAerosolizationaerosol output raterespirable delivered dosemass median aerodynamic diameterDose deliveryJet (fluid)aerosol outputrespiratory systemAerosolNebulizerBiopharmaceutical030228 respiratory systemEnvironmental sciencefine particle fractionnebulizersBiomedical engineeringParticle fractionPharmaceutics
researchProduct